As HB-EGF is produced by the invading cells themselves, it presents a therapeutic target to control the transformation of fibroblasts to reduce their mechanical resistance to invasion by cancer, or to modulate placental invasion in pregnancy related disorders. This evidence concerns the gene HBEGF and cancer.